article thumbnail

Developing new treatment regimens for HIV

European Pharmaceutical Review

In fact, a study published in 2023 in The Lancet HIV revealed that women and men with HIV at age 40 had an average of 39 and 37 years of life left, respectively – only a few years less than that of the general population – if they started antiretroviral therapy (ART) after 2015. World Health Organization. The Global Health Observatory.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

In 2015, the FDA approved Sprout Pharmaceuticals’s Addyi, also known under the generic name flibanserin, for use by pre-menopausal women with hypoactive sexual desire disorder (HSDD). Moreover, despite the buzz generated when Addyi was launched in 2015, only one other drug has since been marketed.